S
Steffen Borrmann
Researcher at University of Tübingen
Publications - 120
Citations - 8673
Steffen Borrmann is an academic researcher from University of Tübingen. The author has contributed to research in topics: Malaria & Plasmodium falciparum. The author has an hindex of 44, co-authored 104 publications receiving 7736 citations. Previous affiliations of Steffen Borrmann include St George's Hospital & Albert Schweitzer Hospital.
Papers
More filters
Journal ArticleDOI
Malaria chemoprophylaxis with tafenoquine: a randomised study.
Bertrand Lell,Bertrand Lell,Jean-François Faucher,Jean-François Faucher,Michel A. Missinou,Michel A. Missinou,Steffen Borrmann,Steffen Borrmann,Oliver Dangelmaier,Oliver Dangelmaier,John Horton,Peter G. Kremsner,Peter G. Kremsner +12 more
TL;DR: Tafenoquine is effective and well tolerated and has the potential to replace currently used drugs for malaria chemoprophylaxis.
Journal ArticleDOI
An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples
MalariaGEN,Ambroise D. Ahouidi,Mozam Ali,Jacob Almagro-Garcia,Jacob Almagro-Garcia,Alfred Amambua-Ngwa,Alfred Amambua-Ngwa,Chanaki Amaratunga,Roberto Amato,Roberto Amato,Lucas Amenga-Etego,Ben Andagalu,Tim J. Anderson,Voahangy Andrianaranjaka,Tobias O. Apinjoh,Cristina V. Ariani,Elizabeth A. Ashley,Sarah Auburn,Gordon A. Awandare,Hampate Ba,Vito Baraka,Vito Baraka,Alyssa E. Barry,Alyssa E. Barry,Alyssa E. Barry,Philip Bejon,Gwladys I. Bertin,Maciej F. Boni,Steffen Borrmann,Teun Bousema,Teun Bousema,OraLee H. Branch,Peter C. Bull,Peter C. Bull,George B.J. Busby,Thanat Chookajorn,Kesinee Chotivanich,Antoine Claessens,Antoine Claessens,David J. Conway,Alister Craig,Alister Craig,Umberto D'Alessandro,Souleymane Dama,Nicholas P. J. Day,Brigitte Denis,Mahamadou Diakite,Abdoulaye Djimde,Christiane Dolecek,Arjen M. Dondorp,Chris Drakeley,Eleanor Drury,Patrick E. Duffy,Diego F. Echeverry,Thomas G. Egwang,Berhanu Erko,Rick M. Fairhurst,Abdul Faiz,Caterina A. Fanello,Mark M. Fukuda,Dionicia Gamboa,Anita Ghansah,Lemu Golassa,Sónia Gonçalves,William L Hamilton,William L Hamilton,G. L. Abby Harrison,Lee Hart,Christa Henrichs,Tran Tinh Hien,Catherine A. Hill,Abraham Hodgson,Christina Hubbart,Mallika Imwong,Deus S. Ishengoma,Scott A. Jackson,Christopher G Jacob,Ben Jeffery,Anna E. Jeffreys,Kimberly J. Johnson,Dushyanth Jyothi,Claire Kamaliddin,Edwin Kamau,Mihir Kekre,Krzysztof Kluczynski,Theerarat Kochakarn,Theerarat Kochakarn,Abibatou Konaté,Dominic P. Kwiatkowski,Dominic P. Kwiatkowski,Myat Phone Kyaw,Pharath Lim,Chanthap Lon,Kovana M. Loua,Oumou Maïga-Ascofaré,Oumou Maïga-Ascofaré,Cinzia Malangone,Magnus Manske,Jutta Marfurt,Kevin Marsh,Kevin Marsh,Mayfong Mayxay,Mayfong Mayxay,Alistair Miles,Alistair Miles,Olivo Miotto,Olivo Miotto,Olivo Miotto,Victor A. Mobegi,Olugbenga A. Mokuolu,Jacqui Montgomery,Ivo Mueller,Paul N. Newton,Thuy Nguyen,Thuy-Nhien Nguyen,Harald Noedl,François Nosten,Rintis Noviyanti,Alexis Nzila,Lynette Isabella Ochola-Oyier,Harold Ocholla,Harold Ocholla,Abraham Oduro,Irene Omedo,Marie A. Onyamboko,Jean-Bosco Ouédraogo,Kolapo Oyebola,Kolapo Oyebola,Richard D. Pearson,Richard D. Pearson,Norbert Peshu,Aung Pyae Phyo,Christopher V. Plowe,Ric N. Price,Ric N. Price,Sasithon Pukrittayakamee,Milijaona Randrianarivelojosia,Julian C. Rayner,Pascal Ringwald,Kirk A. Rockett,Kirk A. Rockett,Katherine Rowlands,Lastenia Ruiz,David L. Saunders,Alex Shayo,Peter Siba,Victoria Simpson,Jim Stalker,Xin-zhuan Su,Colin J. Sutherland,Shannon Takala-Harrison,Livingstone Tavul,Vandana Thathy,Vandana Thathy,Antoinette Tshefu,Federica Verra,Joseph M. Vinetz,Joseph M. Vinetz,Thomas E. Wellems,Jason P. Wendler,Nicholas J. White,Ian J. Wright,William Yavo,Htut Ye +163 more
TL;DR: A new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries aims to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.
Journal ArticleDOI
A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains.
Mark D. Preston,Susana Campino,Samuel Assefa,Diego F. Echeverry,Harold Ocholla,Alfred Amambua-Ngwa,Lindsay B. Stewart,David J. Conway,Steffen Borrmann,Pascal Michon,Issaka Zongo,Jean-Bosco Ouédraogo,Abdoulaye A. Djimde,Ogobara K. Doumbo,François Nosten,Arnab Pain,Teun Bousema,Chris Drakeley,Rick M. Fairhurst,Colin J. Sutherland,Cally Roper,Taane G. Clark +21 more
TL;DR: The mitochondrion and apicoplast genomes of 711 Plasmodium falciparum isolates from 14 countries are analysed and it is found that they are non-recombining and co-inherited.
Journal ArticleDOI
Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast
Steffen Borrmann,Steffen Borrmann,Philip Sasi,Philip Sasi,Leah Mwai,Mahfudh Bashraheil,Ahmed M Abdallah,Steven Muriithi,Henrike Frühauf,Henrike Frühauf,Barbara Schaub,Barbara Schaub,Johannes Pfeil,Johannes Pfeil,Judy Peshu,Warunee Hanpithakpong,Anja Rippert,Elizabeth Juma,Benjamin Tsofa,Moses Mosobo,Brett Lowe,Faith H. A. Osier,Greg Fegan,Niklas Lindegardh,Alexis Nzila,Norbert Peshu,Margaret J. Mackinnon,Margaret J. Mackinnon,Kevin Marsh,Kevin Marsh +29 more
TL;DR: The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both.
Journal ArticleDOI
Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria
Steffen Borrmann,Steffen Borrmann,Steffen Borrmann,Ingrid Lundgren,Ingrid Lundgren,Sunny Oyakhirome,Bénido Impouma,Pierre-Blaise Matsiegui,Pierre-Blaise Matsiegui,Ayola A. Adegnika,Ayola A. Adegnika,Saadou Issifou,Saadou Issifou,Jürgen F. J. Kun,David Hutchinson,Jochen Wiesner,Hassan Jomaa,Peter G. Kremsner,Peter G. Kremsner +18 more
TL;DR: Efficacy appeared to be significantly reduced in children aged 1 to 2 years, with a day 28 cure rate of only 62% for this small subgroup, highlighting the need for continued systematic studies of the current dosing regimen, which should include randomized trial designs.